Suppr超能文献

用于检测成人焦虑症的广泛性焦虑障碍7项(GAD - 7)和2项(GAD - 2)量表。

Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults.

作者信息

Aktürk Zekeriya, Hapfelmeier Alexander, Fomenko Alexey, Dümmler Daniel, Eck Stefanie, Olm Michaela, Gehrmann Jan, von Schrottenberg Victoria, Rehder Rahel, Dawson Sarah, Löwe Bernd, Rücker Gerta, Schneider Antonius, Linde Klaus

机构信息

Institute of General Practice and Health Services Research, TUM School of Medicine and Health, Department of Clinical Medicine, Technical University of Munich, Munich, Germany.

General Practice, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

出版信息

Cochrane Database Syst Rev. 2025 Mar 25;3(3):CD015455. doi: 10.1002/14651858.CD015455.

Abstract

BACKGROUND

Anxiety disorders often remain undetected and can cause substantial burden. Amongst the many anxiety screening tools, the 7-item Generalized Anxiety Disorder (GAD-7) scale and its short version, the 2-item Generalized Anxiety Disorder (GAD-2) scale, are the most frequently used instruments.

OBJECTIVES

Primary: to determine the diagnostic accuracy of GAD-7 and GAD-2 to detect generalised anxiety disorder (GAD) and any anxiety disorder (AAD) in adults. Secondary: to investigate whether their diagnostic accuracy varies by setting, anxiety disorder prevalence, reference standard, and risk of bias; to compare the diagnostic accuracy of GAD-7 and GAD-2; to investigate how diagnostic performance changes with the test threshold.

SEARCH METHODS

We searched MEDLINE, Embase, PubMed-not-MEDLINE subset, and PsycINFO from 1990 to 18 January 2024. We checked reference lists of included studies and review articles.

SELECTION CRITERIA

We included cross-sectional studies conducted in adults, containing diagnostic accuracy information on GAD-7 and/or GAD-2 questionnaires for the target conditions generalised anxiety disorder and/or any anxiety disorder, and allowing the generation of 2x2 tables. The target conditions must have been diagnosed using a structured or semi-structured clinical interview. We excluded case-control studies and studies in which the time elapsed between the index tests and reference standards exceeded four weeks. We excluded studies involving people (1) seeking help in mental health settings or (2) recruited specifically due to mental health symptoms in other settings.

DATA COLLECTION AND ANALYSIS

At least two review authors independently decided on study eligibility, extracted data, and assessed the risk of bias and applicability of included studies. For each questionnaire and each target condition, we present sensitivity and specificity with 95% confidence intervals (95% CI) in forest plots. We used the bivariate model to obtain summary estimates based on cut-offs closest to the recommended values (i.e. within a core range). In secondary analyses, we used the bivariate model and the multiple thresholds model to obtain summary estimates for all available cut-off points. Using the multiple thresholds model, we also calculated the area under the receiver operating characteristic curve to obtain a general indicator of the diagnostic accuracy of GAD-7 and GAD-2.

MAIN RESULTS

We included 48 studies with 19,228 participants from 27 different countries, evaluating the GAD-7 and the GAD-2 in 24 different languages. Seven studies were performed in non-clinical settings, nine in clinical settings recruiting participants across conditions, and 32 in clinical settings with participants having specific conditions. Even after categorisation into three settings, the study populations were substantially different. The most frequently studied populations were people: with epilepsy (nine studies); with cancer (five studies); with cardiovascular disease (five studies); and in primary care regardless of their condition (five studies). We considered the risk of bias low in eight studies, and we had low concerns about the applicability of findings in three studies. Thirty-five studies contributed to the primary analyses of GAD-7 for detecting generalised anxiety disorder (median prevalence 12%); 22 studies to analyses of GAD-7 for any anxiety disorder (median prevalence 19%); 24 studies to analyses of GAD-2 for generalised anxiety disorder (median prevalence 9%); and 19 studies to analyses of GAD-2 for any anxiety disorder (median prevalence 19%). At the recommended cut-off of 10 or higher (or the closest available cut-off), the GAD-7 questionnaire yielded a summary sensitivity of 0.64 (95% CI 0.56 to 0.72) and a summary specificity of 0.91 (95% CI 0.87 to 0.93) in detecting generalised anxiety disorder. For detecting any anxiety disorder, summary sensitivity was 0.48 (95% CI 0.40 to 0.57) and summary specificity 0.91 (95% CI 0.89 to 0.93). At the recommended cut-off of 3 or higher (or the closest available cut-off), the GAD-2 yielded a summary sensitivity of 0.68 (95% CI 0.59 to 0.75) and a summary specificity of 0.86 (95% CI 0.82 to 0.89) for detecting generalised anxiety disorder. For detecting any anxiety disorder, the summary sensitivity was 0.53 (95% CI 0.44 to 0.62) and the summary specificity was 0.89 (95% CI 0.86 to 0.91). The 95% prediction region of GAD-7 for detecting generalised anxiety disorder was larger (indicating pronounced statistical heterogeneity) than for the three other analyses. Specificity varied by setting in the analysis of GAD-7 and GAD-2 for detecting any anxiety disorder, and by reference standard in the analysis of GAD-2 for detecting generalised anxiety disorder. Sensitivity varied with prevalence in the analysis of GAD-7 for generalised anxiety disorder. Other investigations of potential sources of heterogeneity did not show statistically significant associations with test accuracy. In all analyses, sensitivity tended to be higher and specificity lower in participants with specific conditions compared to the other two settings. Overall, the heterogeneity in the subgroup analyses remained high. The area under the receiver operating characteristic curve in the multiple thresholds model was 0.86 (95% CI 0.84 to 0.88) for the GAD-7 scale in detecting generalised anxiety disorder, and 0.80 (95% CI 0.78 to 0.82) in detecting any anxiety disorders. For the GAD-2 scale, the value was 0.82 (95% CI 0.81 to 0.86) for detecting generalised anxiety disorder, and 0.77 (95% CI 0.76 to 0.82) for detecting any anxiety disorders. Comparative bivariate analyses revealed no statistically significant differences between the diagnostic test accuracy of GAD-7 and GAD-2.

AUTHORS' CONCLUSIONS: The GAD-7 and the GAD-2 scales have been tested in numerous languages and different populations. Overall, the GAD-7 and the GAD-2 seem to have acceptable or good diagnostic accuracy for both generalised anxiety disorder and any anxiety disorder. The GAD-2 scale seems to have similar diagnostic accuracy as the GAD-7 scale. However, due to the diversity of the included studies and the heterogeneity of our findings, our summary estimates of sensitivity and specificity should be interpreted as rough averages. The performance of GAD-7 and GAD-2 may deviate substantially from these values in specific situations.

摘要

背景

焦虑症常常未被发现,且会造成相当大的负担。在众多焦虑筛查工具中,7项广泛性焦虑障碍(GAD-7)量表及其简短版本,即2项广泛性焦虑障碍(GAD-2)量表,是最常用的工具。

目的

主要目的:确定GAD-7和GAD-2检测成人广泛性焦虑障碍(GAD)和任何焦虑障碍(AAD)的诊断准确性。次要目的:调查其诊断准确性是否因环境、焦虑症患病率、参考标准和偏倚风险而异;比较GAD-7和GAD-2的诊断准确性;研究诊断性能如何随测试阈值变化。

检索方法

我们检索了1990年至2024年1月18日的MEDLINE、Embase、PubMed非MEDLINE子集和PsycINFO。我们检查了纳入研究和综述文章的参考文献列表。

选择标准

我们纳入了针对成年人开展的横断面研究,这些研究包含关于GAD-7和/或GAD-2问卷针对目标疾病广泛性焦虑障碍和/或任何焦虑障碍的诊断准确性信息,并允许生成2×2表格。目标疾病必须使用结构化或半结构化临床访谈进行诊断。我们排除了病例对照研究以及索引测试和参考标准之间的时间间隔超过四周的研究。我们排除了涉及以下人群的研究:(1)在心理健康机构寻求帮助的人;(2)在其他环境中因心理健康症状而专门招募的人。

数据收集与分析

至少两名综述作者独立决定研究的纳入资格、提取数据,并评估纳入研究的偏倚风险和适用性。对于每个问卷和每个目标疾病,我们在森林图中呈现敏感性和特异性以及95%置信区间(95%CI)。我们使用双变量模型根据最接近推荐值(即在核心范围内)的截断值获得汇总估计。在次要分析中,我们使用双变量模型和多阈值模型为所有可用的截断点获得汇总估计。使用多阈值模型,我们还计算了受试者工作特征曲线下的面积,以获得GAD-7和GAD-2诊断准确性的一般指标。

主要结果

我们纳入了48项研究,来自27个不同国家的19228名参与者,以24种不同语言对GAD-7和GAD-2进行了评估。7项研究在非临床环境中进行,9项在临床环境中招募各种情况下的参与者,32项在临床环境中招募患有特定疾病的参与者。即使分类为三种环境后,研究人群也存在很大差异。研究最频繁的人群是:患有癫痫的人(9项研究);患有癌症的人(5项研究);患有心血管疾病的人(5项研究);以及初级保健中的人(无论其疾病情况,5项研究)。我们认为8项研究的偏倚风险较低,我们对3项研究结果的适用性担忧较低。35项研究为检测广泛性焦虑障碍的GAD-7的主要分析做出了贡献(中位患病率12%);22项研究为检测任何焦虑障碍的GAD-7分析做出了贡献(中位患病率19%);24项研究为检测广泛性焦虑障碍的GAD-2分析做出了贡献(中位患病率9%);19项研究为检测任何焦虑障碍的GAD-2分析做出了贡献(中位患病率19%)。在推荐的截断值10或更高(或最接近的可用截断值)时,GAD-7问卷在检测广泛性焦虑障碍时的汇总敏感性为0.64(95%CI 0.56至0.72),汇总特异性为0.91(95%CI 0.87至0.93)。对于检测任何焦虑障碍,汇总敏感性为0.48(95%CI 0.40至0.57),汇总特异性为0.91(95%CI 0.89至0.93)。在推荐的截断值3或更高(或最接近的可用截断值)时,GAD-2在检测广泛性焦虑障碍时的汇总敏感性为0.68(95%CI 0.59至0.75),汇总特异性为0.86(95%CI 0.82至0.89)。对于检测任何焦虑障碍,汇总敏感性为0.53(95%CI 0.44至0.62),汇总特异性为0.89(95%CI 0.86至0.91)。GAD-7检测广泛性焦虑障碍时的95%预测区间比其他三项分析更大(表明存在明显的统计异质性)。在检测任何焦虑障碍的GAD-7和GAD-2分析中,特异性因环境而异,在检测广泛性焦虑障碍的GAD-2分析中,特异性因参考标准而异。在检测广泛性焦虑障碍的GAD-7分析中,敏感性随患病率而变化。对其他潜在异质性来源的调查未显示与测试准确性有统计学上的显著关联。在所有分析中,与其他两种环境相比,患有特定疾病的参与者的敏感性往往更高,特异性更低。总体而言,亚组分析中的异质性仍然很高。多阈值模型中,GAD-7量表检测广泛性焦虑障碍时受试者工作特征曲线下的面积为0.86(9五%CI 0.84至0.88),检测任何焦虑障碍时为0.80(95%CI 0.78至0.82)。对于GAD-2量表,检测广泛性焦虑障碍时的值为0.82(95%CI 0.81至0.86),检测任何焦虑障碍时为0.77(95%CI 0.76至0.82)。比较双变量分析显示GAD-7和GAD-2的诊断测试准确性之间没有统计学上的显著差异。

作者结论

GAD-7和GAD-2量表已在多种语言和不同人群中进行了测试。总体而言,GAD-7和GAD-2对于广泛性焦虑障碍和任何焦虑障碍似乎都具有可接受或良好的诊断准确性。GAD-2量表似乎具有与GAD-7量表相似的诊断准确性。然而,由于纳入研究的多样性和我们研究结果的异质性,我们对敏感性和特异性的汇总估计应解释为大致平均值。在特定情况下,GAD-7和GAD-2的性能可能与这些值有很大偏差。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验